Lv51
1320 积分 2023-06-12 加入
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
4小时前
待确认
Construction of tumor-cell nucleus targeting lanthanide nano-prodrugs with lutetium-177 labelling for high-efficient tumor fluorescence-localization and radionuclide therapy
5天前
已完结
[177Lu]Lu DOTATOC PRRT with PARP inhibitors in small cell lung cancer
5天前
已完结
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
1个月前
已完结
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
1个月前
已完结
Fe/Cu Bimetallic Nanozyme Co‐Assembled with 177Lu and Tanshinone for Quadruple‐Synergistic Tumor‐Specific Therapy
1个月前
已完结
Tumor cell-derived lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
1个月前
已完结
A radionuclide-labeled nanomedicine for STING pathway activation- and oxygenation-augmented orthotopic cancer radioisotope-immunotherapy
1个月前
已完结
Construction of tumor-cell nucleus targeting lanthanide nano-prodrugs with lutetium-177 labelling for high-efficient tumor fluorescence-localization and radionuclide therapy
1个月前
已完结
Tumor microenvironment-responsive precise delivery nanocarrier potentiating synchronous radionuclide therapy and chemotherapy against cancer
1个月前
已完结
皖公网安备34019202002308
